MedTrace Logo

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

NCT01624727 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2017-09-27

No results posted yet for this study

Summary

The purpose of the study is to target inflammation to reduce progression of noncalcified plaque in the coronary arteries using omega-3 fatty acid supplementation compared to standard of care.

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega 3 acid ethyl esters

Lovaza 3.6 g daily

Sponsors & Collaborators

Principal Investigators

  • Francine K Welty, MD, PhD · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2015-01-15
Completion
2015-01-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01624727 on ClinicalTrials.gov